Hong Kong, China; Research Site:
A Study of Avastin (Bevacizumab) and TACE Treatment in Patients With Liver Cancer.
Hong Kong, China; Research Site:
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Marseille, France; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Montpellier Cedex 5, France; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Reims Cedex, France; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Rennes, France; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Villejuif, France; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Kowloon, Hong Kong; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Shatin, Hong Kong; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Cheras, Kuala Lumpur; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Nilai, Negeri Sembilan; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Cebu City, Philippines; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Davo City, Philippines; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Manila, Philippines; Research Site:
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Quezon, Philippines; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Gyeonggi-Do, Republic of Korea; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Seoul, Republic of Korea; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Seoul, Republic of Korea; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Seoul, Republic of Korea; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Singapore, Singapore; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Singapore, Singapore; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Singapore, Singapore; Research Site:
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Kaohsiung, Taiwan; Research Site:
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Kueishan, Taiwan; Research Site:
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Kueishan, Taiwan; Research Site:
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Tainan, Taiwan; Research Site:
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Tainan, Taiwan; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Tainan, Taiwan; Research Site:
A Study of Xeloda (Capecitabine) and PEGASYS in Treatment-Naive Patients With Advanced Liver Cancer
Taipei, Taiwan; Research Site:
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Taipei, Taiwan; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Taipei, Taiwan; Research Site:
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Taipei City, Taiwan; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Birmingham, United Kingdom; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
London, United Kingdom; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
Northwood, United Kingdom; Local Institution
Study of BMS-582664 or Doxorubicin in Locally Advanced or Metastatic Hepatocellular Cancer
